Industry’s Destination to Discover & Develop Best-In-Class Drugs for Immuno-Inflammatory Skin Disease
As the field surges with clinical and commercial momentum, from Sanofi’s continued success with Dupixent, Corvus' promising Phase 1 data on Soquelitinib, and landmark M&A deals like Gilead’s $1.7B inflammation partnership with LEO Pharma, the 9th Dermatology Drug Development Summit returned to unite 120+ leading experts committed to solving the most pressing R&D bottlenecks in dermatology drug development.
Industry leaders who joined in November 2025 explored disease heterogeneity, novel therapies and MoA, safety and the evolving reg landscape, as well as deep dives into the latest preclinical and clinical findings across rare and common disease (including AD, Psoriasis, HS, Vitiligo, Pemphigus Nodularis, Bullous Pemphigoid, Alopecia Areata).
From bispecifics to oligos, discover the modalities reshaping derma pipelines and hear insights from AbbVie, Sanofi, Takeda, Incyte, Merck, and others across discovery, preclinical, translational, clinical, and medical affairs.
The Dermatology Drug Development Summit provides an opportunity to engage in in-depth, scientifically grounded discussions on the evolving treatment landscape for inflammatory skin diseases. The program facilitates meaningful exchange on emerging mechanisms, therapeutic innovation, and clinical translation, with focused sessions addressing key development challenges in areas such as immune modulation, barrier dysfunction, and chronic inflammation.
Shawn Seong, Chief Executive Officer,
Shaperon Inc
The 2025 Industry-Leading Speakers:
2025 Partners:
Other Events in the Series
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.